In this segment, Dr. Peter Voorhees introduces the Targeted™ Oncology Investigator Perspectives program and outlines the evolving treatment landscape in newly diagnosed multiple myeloma, including the movement of novel therapies into earlier lines of treatment.
Daniel DeAngelo, MD, PhD, discusses how the field of AML is moving away from traditional chemotherapy and toward targeted triplet therapies.
At the 2026 IMS meeting, Sagar Lonial, MD, discusses the FDA approval of iberdomide, early enthusiasm for its use, and the CELMoD trials clinicians should watch.
Martin Dietrich, MD, PhD, tells community oncologists to build in access to second opinions, often by telemedicine, and says he would rather be slow and right than fast and wrong, because a less effective first choice drives resistance that later agents cannot fully recover.
Ticiana Leal, MD, argues that trials need more patient-reported outcomes and quality of life measures, since patients with ROS1-positive advanced non-small cell lung cancer now stay on oral therapy for years and the effect on daily life is poorly captured.
As Leukemia and Lymphoma Awareness Month draws to a close, Daniel DeAngelo, MD, PhD, discusses the key trends in acute lymphoblastic leukemia treatment.
Pieter Sonneveld, MD, PhD, discusses CAR T-cell therapy and bispecific antibodies moving to frontline myeloma care.
Trispecific T-cell engagers target 2 tumor antigens or dual immune targets, aiming to reduce antigen-loss resistance and boost cancer killing beyond bispecifics.
Jeffrey V. Matous, MD, discusses moving fixed-duration T-cell–redirecting therapy into frontline multiple myeloma treatment and the persistent challenge of ultra-high-risk disease.
Luciano Costa, MD, of UAB, explains why most patients with myeloma will soon need just 1 or 2 lines of therapy to restore normal life expectancy.
C. Ola Landgren, MD, PhD, explains how MRD negativity and newer therapies may move multiple myeloma care past the question of transplant eligibility.
Peter Voorhees, MD, discusses the CERVINO trial of the bispecific antibody etentamig that he is presenting at the IMS conference.
Geoffrey Y. Ku, MD, discusses the state of biomarkers in gastric/gastroesophageal junction cancers and where precision medicine still falls short.
Hans Lee, MD, Sarah Cannon Research Institute, explains new IMS/IMWG cure criteria for myeloma and the meaning of durable CAR-T responses in these patients.
Gurbakhash Kaur, MD, discusses how quadruplet regimens, CAR T-cell therapy, and bispecific antibodies are reshaping the role of autologous transplant in multiple myeloma.
Shubham Pant, MD, discusses the expanding pipeline of RAS-directed agents beyond daraxonrasib for patients with pancreatic cancer.
Hans Lee, MD, discusses the importance of BCMA-targeted therapy and the differences between CAR T and bispecific antibody therapy in multiple myeloma.
Geoffrey Y. Ku, MD, breaks down HER2-targeted and MSI-high perioperative strategies in gastroesophageal cancer, including new PHERFLOT trial data.
CAR T and bispecific T-cell engagers move earlier in blood cancer care, reshaping sequencing and expanding access beyond academic centers.
Martin Dietrich, MD, PhD, says he manages neurologic adverse events reactively rather than proactively, because he cannot predict who will develop them and because on-target effects tend to appear early.
Martin Dietrich, MD, PhD, separates an agent working in the brain from an agent acting on the brain, and explains that structural overlap in the adenosine triphosphate (ATP) binding pocket makes TRK family inhibition difficult to avoid.
David R. Gandara, MD, explains why KRAS G12C predicts immunotherapy benefit in non–small cell lung cancer and what EMPOWER-Lung 1 means for trial design.
Jonathan Villena-Vargas, MD, explains how a team-based training model makes subcostal robotic lung surgery safe, even in complex neoadjuvant cases.
David DiBardino, MD, explains how a hafnium compound is being tested alongside chemoradiation and durvalumab to address low response rates in locally advanced disease.
AI streamlines oncology workflows, cuts admin burden, and hints at smarter interoperability—linking fragmented records for quicker clinical decisions.
E. Anders Kolb, MD, on blood cancer research's legacy in oncology and the racial, geographic barriers still limiting patient access to care.
Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center.
Saro Armenian, DO, MPH, explains the importance of screening for issues such as secondary skin cancers in patients who received stem cell transplant.
Geoffrey Y. Ku, MD, discusses MATTERHORN, which established perioperative durvalumab plus FLOT as standard care for resectable gastric/GEJ adenocarcinoma.
Jonathan Villena-Vargas, MD, explains how a rib-sparing robotic approach cuts post-thoracotomy pain and opioid use for thoracic surgery patients.